Please assess the completion status of the following clinical trial:

Trial Title: MANTA Ultrasound Closure Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Candidate for elective or planned (i.e., not emergent or urgent) percutaneous transcatheter valve replacement (TAVR) via a 10-20F device or sheath (12-25F OD) with common femoral artery approach~* Vessel size would allow for access for the MANTA VCD based on vessel size as determined by baseline CTA: minimum vessel diameter of 5mm for the 14F MANTA VCD and 6mm for the 18F MANTA VCD~* Understand and sign the study specific written informed consent form and PHI authorization~* Able and willing to fulfill the follow-up requirements~Exclusion Criteria:~* Patients known to be pregnant or lactating~* Patients who have a systemic infection or a local infection at or near the access site~* Patients with significant anemia (hemoglobin ≤10 g/DL)~* Patients who are morbidly obese or cachectic (BMI \>40 or \<20kg/m2)~* Patients with a known bleeding disorder including thrombocytopenia (platelet count \<100,000 cells/UL), thrombasthenia, hemophilia, or von Willebrand disease~* Patients with allergy to bovine materials or any other device material, including collagen and/or collagen products, polyglycolic or polylactic acid, stainless steel or nickel~* Patients with a femoral artery puncture in target groin within the prior 30 days, prior vascular closure device placement in the target common femoral artery within 3 months, or any prior target femoral artery access-related complication~* Patients who have undergone use of an intra-aortic balloon pump (IABP) through the arterial access site within 30 days prior to the baseline evaluation.~* Patients who have a Common Femoral Artery (CFA) with visible calcium and/or tortuosity, as determined by baseline CTA, precluding safe access and likely to interact with large bore access site arteriotomy, determined by investigator.~* Patients with previous iliofemoral intervention in region of access site, including but not limited to prior atherectomy, stenting, surgical or grafting procedures in the access area~* Patients in whom oral anticoagulation therapy cannot be stopped for the peri procedural period or patients with INR \>1.8 at the time of the procedure~* Patients who are unable to ambulate at least 6 meters without assistance at baseline~* Patients with renal insufficiency (serum creatinine \>2.5 mg/dl) or on dialysis therapy~* Patients with existing nerve damage in the ipsilateral leg~* Patients with a further planned endovascular procedure within the next 30 days~* Patients who have already participated in this IDE study~* Patients who are currently participating in another clinical study of an unapproved investigational device or drug that has not concluded the follow-up period or patient currently participating in another clinical study likely to influence hemostasis and vascular complications~* Patients who cannot adhere to or complete the investigational protocol for any reason including but not limited to geographical residence, psychiatric condition or life threatening disease~* Patients who have a common femoral artery \<5mm in diameter for the 14F MANTA VCD or \<6 mm in diameter for the 18F MANTA VCD, common femoral artery stenosis resulting in a vessel diameter \<5mm in diameter for the 14F MANTA VCD or \<6 mm in diameter for the 18F MANTA VCD, or \> 50% diameter femoral or iliac artery stenosis~* Patients in whom, during initial access of the artery, arteriotomy and surrounding anatomy cannot be visualized and identified clearly under U/S imaging and/or if the vertical depth from the surface of the skin to target area of the common femoral artery measures greater than 6cm

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ultrasound Closure (Type: EXPERIMENTAL): Open label, single arm study using ultrasound guidance during MANTA device deployment.

Based on this trial design, predict the completion outcome and termination type (if applicable).